[The cutting-edge of medicine anti-MRSA agents; how to select and how to use].
Department of Clinical Infectious Diseases, Showa University, School of Medicine, Japan.
Yoshihito
Y
Niki
D000081:Acetamides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D003428:Cross Infection / Q000188:drug therapy; D017576:Daptomycin / Q000627:therapeutic use; D003982:Dibekacin / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D000069349:Linezolid; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D023303:Oxazolidinones / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy*; D017334:Teicoplanin / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use
D000081:Acetamides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D003982:Dibekacin; D017334:Teicoplanin; D014640:Vancomycin; C031986:arbekacin; D000069349:Linezolid; D017576:Daptomycin